Guggenheim analyst Michael Schmidt initiates coverage on $SpringWorks Therapeutics (SWTX.US)$ with a buy rating, and sets the target price at $78.
According to TipRanks data, the analyst has a success rate of 49.4% and a total average return of 16.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $SpringWorks Therapeutics (SWTX.US)$'s main analysts recently are as follows:
Despite ongoing political and rate uncertainties which persistent as an overhang, the overall health of the Biopharma sector is seen as significantly better compared to its 2022 lows. For stocks under its review, preference continues toward those in late-stage clinical or early launch phases. However, Phase 1 clinical programs that present derisking data and impending catalysts are now viewed as key areas gaining investor interest.
The firm has slightly revised its Ogsiveo sales projections, now accounting for a reduced impact from ovarian granulosa cell tumor contribution and anticipating a slower sales increase in the EU by 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Guggenheim分析師Michael Schmidt首次給予$SpringWorks Therapeutics (SWTX.US)$買入評級,目標價78美元。
根據TipRanks數據顯示,該分析師近一年總勝率為49.4%,總平均回報率為16.1%。
此外,綜合報道,$SpringWorks Therapeutics (SWTX.US)$近期主要分析師觀點如下:
儘管持續的政治和利率不確定性仍然是一個懸而未決的問題,但與2022年的低點相比,生物製藥行業的整體健康狀況被認爲要好得多。對於正在審查的股票,繼續偏向處於臨牀後期或早期上市階段的股票。但是,提供去風險數據和即將出現的催化劑的1期臨牀項目現在被視爲引起投資者興趣的關鍵領域。
該公司略微修改了其Ogsiveo的銷售預測,現在考慮到卵巢顆粒細胞瘤貢獻的影響有所減少,並預計到2025年歐盟的銷售增長將放緩。
提示:
TipRanks為獨立第三方,提供金融分析師的分析數據,並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議,僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級,分析師星級代表分析師所有推薦的過往表現,通過分析師的總勝率和平均回報率综合計算得出,星星越多,則該分析師過往表現越優異,最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否,取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合,並根據評級變化對組合進行調整,在近一年中該投資組合所獲得的回報率。